<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284478</url>
  </required_header>
  <id_info>
    <org_study_id>NCRVA-2011-Ozurdex-16-1</org_study_id>
    <nct_id>NCT01284478</nct_id>
  </id_info>
  <brief_title>Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery</brief_title>
  <official_title>Phase 2 Study of Ozurdex for Combined Pseudophakic Cystoid Macula Edema and Diabetic Macula Edema After Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern California Retina Vitreous Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern California Retina Vitreous Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine where a sustained steroid delivery system
      (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients
      after Cataract Surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BEST CORRECTED VISUAL ACUITY (ETDRS)</measure>
    <time_frame>AT DAY 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RETINAL THICKNESS MEASURED BY SPECTRAL DOMAIN OPTICAL TOMOGRAPHY</measure>
    <time_frame>90 and 180 DAYS</time_frame>
    <description>CENTRAL FOVEAL THICKNESS AND MACULAR VOULUME</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pseudophakic Cystoid Macular Edema,</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Dexamethasone Implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be treated with the Ozurdex (Dexamethasone Implant)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Implant</intervention_name>
    <description>Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally</description>
    <arm_group_label>Dexamethasone Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY (WITHIN 4-10
             WEEKS AFTER SURGERY

          -  VISUAL ACUITY WORSE THAN 20/32

        Exclusion Criteria:

          -  VISUAL ACUITY WORSE THAN 20/200

          -  MODERATE OR SEVERE GLAUCOMA (AS DEFINED AS USING &gt;2 TOPICAL GLAUCOMA MEDIATIONS.

          -  USE OF SYSTEMIC, PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF
             ENROLLMENT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul Khurana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern California Retina Vitreous Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <name_title>RAHUL KHURANA, M.D. / PRINCIPAL INVESTIGATOR</name_title>
    <organization>NORTHERN CALIFORNIA RETINA VITREOUS ASSOCIATES</organization>
  </responsible_party>
  <keyword>pseudophakic cystoid macular edema, diabetic macular edema, Irvine Gass Syndrome, cataract surgery, ozurdex, dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 16, 2015</submitted>
    <returned>February 28, 2015</returned>
    <submitted>March 10, 2015</submitted>
    <returned>March 20, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

